Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 2:03 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,349 matching trials from the live ClinicalTrials.gov search.
Filters: New Haven, Connecticut Clear all
Completed Phase 3 Interventional

Neurosurgery Patient Outcomes in Treating Spinal Disorders

NCT01220921
View directory record Official record
Conditions
Symptomatic Lumbar Disc Herniation, Symptomatic Grade I Lumbar Spondylolisthesis
Interventions
Lumbar Discectomy, Single-level lumbar fusion
Procedure
Lead sponsor
Greenwich Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
12
States / cities
San Francisco, California • Greenwich, Connecticut • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Nov 3, 2026, 2:03 PM EST
Completed No phase listed Observational

Associations of Socioeconomic Adversity and Sleep With Allostatic Load Among Toddlers

NCT03419871
View directory record Official record
Conditions
Sleep Disorder
Interventions
Monitoring Sleep, stress biomarkers
Other
Lead sponsor
Yale University
Other
Eligibility
12 Months to 15 Months
Enrollment
100 participants
Timeline
2015 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Nov 3, 2026, 2:03 PM EST
Recruiting Early Phase 1 Interventional

Regulation of Brain Glucose Metabolism in Type 1 Diabetes

NCT05317455
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Hypoglycemia Unawareness
Interventions
Dichloroacetate
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Nov 3, 2026, 2:03 PM EST
Completed No phase listed Observational Results available

Validation of a Rapid Quantitative Test for Loss of Smell in COVID-19 Subjects

NCT04431908
View directory record Official record
Conditions
COVID-19
Interventions
olfactory device
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
1,320 participants
Timeline
2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 2 Interventional Results available

A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)

NCT04299464
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD)
Interventions
Placebo, RO7017773
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
15 Years to 45 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
Phoenix, Arizona • New Haven, Connecticut • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Nov 3, 2026, 2:03 PM EST
Terminated Phase 3 Interventional Results available

Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)

NCT03642132
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Chemotherapy + avelumab followed by avelumab + talazoparib, Chemotherapy followed by talazoparib maintenance, Chemotherapy + bevacizumab followed by bevacizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
46
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Nov 3, 2026, 2:03 PM EST
Suspended Phase 1 Interventional

A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

NCT07395258
View directory record Official record
Conditions
Solid Tumors
Interventions
BI 3923948, Ezabenlimab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
2
States / cities
New Haven, Connecticut • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 3, 2026, 2:03 PM EST
Terminated Phase 3 Interventional Results available

Nutrition and Prostate Cancer

NCT03532308
View directory record Official record
Conditions
Prostate Cancer
Interventions
Fermented Soy, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
New Haven, Connecticut • New London, Connecticut • Wakefield, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 2 Interventional Results available

Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Osteoarthritis

NCT04627038
View directory record Official record
Conditions
Osteoarthritis
Interventions
LY3556050, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
38
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 3 Interventional Results available

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

NCT03523585
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab deruxtecan, Capecitabine, Lapatinib, Trastuzumab
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
41
States / cities
Chandler, Arizona • Los Angeles, California • Monterey, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 3, 2026, 2:03 PM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Personalized Therapy Study - Intrinsic Antitachycardia Pacing Post-Approval Study (iATP PAS)

NCT04496518
View directory record Official record
Conditions
Ventricular Tachycardia
Interventions
Intrinsic Antitachycardia Pacing (iATP) Therapy
Device
Lead sponsor
Medtronic
Industry
Eligibility
Not listed
Enrollment
2,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
51
States / cities
Chandler, Arizona • Little Rock, Arkansas • Chula Vista, California + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 3 Interventional

Homocysteine Study (HOST)

NCT00032435
View directory record Official record
Conditions
End Stage Renal Disease, Renal Failure
Interventions
PAL-40 Active, PAL-40 Placebo
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
21 Years and older
Enrollment
2,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
36
States / cities
Birmingham, Alabama • Menlo Park, California • Palo Alto, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2010 · Synced Nov 3, 2026, 2:03 PM EST
Completed No phase listed Observational

Digitalization of Measuring Physical Performance

NCT06564350
View directory record Official record
Conditions
Physical Performance
Interventions
IMU (Inertial Measurement Unit) sensors
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Learn About How Itraconazole Affects the Blood Level of Study Medicine (PF-07817883) in Healthy Adults.

NCT05822440
View directory record Official record
Conditions
Healthy
Interventions
PF-07817883, Itraconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 4, 2024 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy Adults

NCT05652660
View directory record Official record
Conditions
Healthy
Interventions
ARV-471, Rosuvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 2Phase 3 Interventional

Enhancing Emergency Practitioner (EP)-Performed Alcohol Interventions in the Emergency Department (ED)

NCT00261859
View directory record Official record
Conditions
Harmful Drinking
Interventions
BNI
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Nov 3, 2026, 2:03 PM EST
Completed No phase listed Observational Results available

Perioperative Blood Pressures and Chronic Hypertension

NCT02136810
View directory record Official record
Conditions
Hypertension
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 4 Interventional Results available

Safety and Pharmacokinetic Study of Oral Morphine Sulfate in Pediatric Subjects

NCT01322360
View directory record Official record
Conditions
Pain
Interventions
Morphine Sulfate
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
2 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Stanford, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Nov 3, 2026, 2:03 PM EST
Active, not recruiting Phase 3 Interventional

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

NCT06132958
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Sacituzumab tirumotecan, Doxorubicin, Paclitaxel, Nab-paclitaxel, Rescue medications
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
43
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 3 Interventional Results available

MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer

NCT01805076
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Triple-negative Breast Cancer
Interventions
Breast surgery, Magnetic resonance imaging, Mammography
Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
179
States / cities
Gilbert, Arizona • Jonesboro, Arkansas • Antioch, California + 141 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 4 Interventional Results available

Counseling for Primary Care Office-based Buprenorphine

NCT00595764
View directory record Official record
Conditions
Opiate Dependence
Interventions
Manual-guided Physician Management (PM), Physician Management (PM) combined with on-site manual-guided Cognitive Behavioral Therapy (CBT)
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Nov 3, 2026, 2:03 PM EST
Recruiting Phase 3 Interventional

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

NCT05561387
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
397
States / cities
Anchorage, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 287 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Nov 3, 2026, 2:03 PM EST
Terminated Phase 3 Interventional Results available

OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)

NCT02097121
View directory record Official record
Conditions
Urinary Incontinence, Urinary Bladder, Overactive
Interventions
BOTOX®
Biological
Lead sponsor
Allergan
Industry
Eligibility
12 Years to 17 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
8
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Nov 3, 2026, 2:03 PM EST
Completed Not applicable Interventional Results available

Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure

NCT04514458
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
Best practice alert for the notification of patient HFrEF and recommended evidence-based therapies (NO drugs are being administered in this trial)
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
1,410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Nov 3, 2026, 2:03 PM EST